First Documented Case of Successful Dual Therapy With Upadacitinib and Mirikizumab for Multi-Refractory Ulcerative Proctitis

This article reports the first documented case of successful dual therapy with upadacitinib (JAK inhibitor) and mirikizumab (anti-IL-23) for multi-refractory ulcerative proctitis, demonstrating clinical remission, biomarker normalization, and endoscopic improvement after failure of conventional therapies.